As the CD226–TIGIT axis is centrally involved in the Th1/Th17 balance in cancer and autoimmunity, possible side effects of TIGIT blockade include exacerbation of autoimmune diseases similar to combined PD-1/CTLA-4 blockade [53]. Here, CTLA4 is linked to cancer.